ES520692A0 - Un procedimiento de preparacion de conjugados inmunoenzimaticos. - Google Patents

Un procedimiento de preparacion de conjugados inmunoenzimaticos.

Info

Publication number
ES520692A0
ES520692A0 ES520692A ES520692A ES520692A0 ES 520692 A0 ES520692 A0 ES 520692A0 ES 520692 A ES520692 A ES 520692A ES 520692 A ES520692 A ES 520692A ES 520692 A0 ES520692 A0 ES 520692A0
Authority
ES
Spain
Prior art keywords
conjugates
preparation
procedure
antibody
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES520692A
Other languages
English (en)
Other versions
ES8405071A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9272107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES520692(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of ES8405071A1 publication Critical patent/ES8405071A1/es
Publication of ES520692A0 publication Critical patent/ES520692A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
ES520692A 1982-03-17 1983-03-16 Un procedimiento de preparacion de conjugados inmunoenzimaticos. Granted ES520692A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8204547A FR2523445A1 (fr) 1982-03-17 1982-03-17 Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues

Publications (2)

Publication Number Publication Date
ES8405071A1 ES8405071A1 (es) 1984-05-16
ES520692A0 true ES520692A0 (es) 1984-05-16

Family

ID=9272107

Family Applications (1)

Application Number Title Priority Date Filing Date
ES520692A Granted ES520692A0 (es) 1982-03-17 1983-03-16 Un procedimiento de preparacion de conjugados inmunoenzimaticos.

Country Status (27)

Country Link
US (1) US4762707A (es)
EP (1) EP0089880B1 (es)
JP (1) JPH0653677B2 (es)
KR (1) KR910000029B1 (es)
AT (1) ATE27915T1 (es)
AU (1) AU563356B2 (es)
CA (1) CA1216791A (es)
CS (1) CS268656B2 (es)
DD (1) DD209578A5 (es)
DE (1) DE3372175D1 (es)
DK (1) DK166966B1 (es)
EG (1) EG15882A (es)
ES (1) ES520692A0 (es)
FI (1) FI830897L (es)
FR (1) FR2523445A1 (es)
GR (1) GR77119B (es)
HU (1) HU189246B (es)
IE (1) IE54624B1 (es)
IL (1) IL68106A0 (es)
MA (1) MA19742A1 (es)
NO (1) NO166618C (es)
NZ (1) NZ203586A (es)
OA (1) OA07388A (es)
PH (1) PH18890A (es)
PL (1) PL142316B1 (es)
PT (1) PT76394B (es)
ZA (1) ZA831833B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
DE3612643A1 (de) * 1985-12-05 1987-06-11 Mueller Lierheim Kg Biolog Lab Traegerkoerper, der durch kovalent an seine oberflaeche gebundene antikoerper bioaktiviert ist
WO1987004164A1 (en) * 1986-01-06 1987-07-16 The University Of Melbourne Technetium-antibody conjugate
US5716990A (en) * 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
FR2624010B1 (fr) * 1987-12-07 1991-07-05 Fabre Pierre Cosmetique Compositions topiques heterogenes a base de microgranules de cafeine et/ou de ses derives, utiles comme amincissant et/ou dans le traitement de la cellulite, ainsi que leur preparation
DE3807904A1 (de) * 1988-03-10 1989-09-21 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0449998A4 (en) * 1989-06-30 1992-01-15 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
AU595786B3 (en) * 1990-01-10 1990-03-12 Chung Ming Pan Spray head assembly
AU663582B2 (en) * 1992-03-04 1995-10-12 Akzo N.V. In vivo binding pair pretargeting
US5965106A (en) * 1992-03-04 1999-10-12 Perimmune Holdings, Inc. In vivo binding pair pretargeting
AU4375293A (en) * 1992-05-13 1993-12-13 Beth Israel Hospital Association, The Targeted activated species cytotoxicity
CA2149922C (en) * 1992-12-04 2007-05-15 Thomas W. Macallister Genetically engineered glutaminase and its use in antiviral and anticancer therapy
DK75593D0 (es) * 1993-06-25 1993-06-25 Novo Nordisk As
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1891560A2 (en) * 2005-04-27 2008-02-27 Avici Systems, Inc. An application specific reconfigurable network processor
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
RU2689689C2 (ru) * 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS53124682A (en) * 1977-04-08 1978-10-31 Asahi Chem Ind Co Ltd Preparation of complex of enzyme and bioactive substance and its use
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5590858A (en) * 1978-12-29 1980-07-09 Asahi Chem Ind Co Ltd Method of measuring substance
JPS588395B2 (ja) * 1979-08-08 1983-02-15 大日本製薬株式会社 マレイミド安息香酸誘導体の製法
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique

Also Published As

Publication number Publication date
CA1216791A (en) 1987-01-20
FR2523445A1 (fr) 1983-09-23
ES8405071A1 (es) 1984-05-16
NO166618B (no) 1991-05-13
NZ203586A (en) 1986-08-08
EP0089880B1 (fr) 1987-06-24
KR910000029B1 (ko) 1991-01-19
EG15882A (en) 1986-09-30
FI830897A0 (fi) 1983-03-17
GR77119B (es) 1984-09-07
MA19742A1 (fr) 1983-10-01
PT76394B (fr) 1985-12-05
AU1250483A (en) 1983-09-22
ATE27915T1 (de) 1987-07-15
JPH0653677B2 (ja) 1994-07-20
DE3372175D1 (en) 1987-07-30
IE830531L (en) 1983-09-17
NO830935L (no) 1983-09-19
DK121683A (da) 1983-09-18
NO166618C (no) 1991-08-21
PL142316B1 (en) 1987-10-31
AU563356B2 (en) 1987-07-09
IL68106A0 (en) 1983-06-15
FR2523445B1 (es) 1985-01-11
CS268656B2 (en) 1990-04-11
PT76394A (fr) 1983-04-01
IE54624B1 (en) 1989-12-20
KR840003815A (ko) 1984-10-04
PL241047A1 (en) 1983-10-10
PH18890A (en) 1985-10-25
DD209578A5 (de) 1984-05-16
DK166966B1 (da) 1993-08-09
JPS58208238A (ja) 1983-12-03
HU189246B (en) 1986-06-30
FI830897L (fi) 1983-09-18
CS173783A2 (en) 1989-08-14
EP0089880A1 (fr) 1983-09-28
DK121683D0 (da) 1983-03-16
US4762707A (en) 1988-08-09
OA07388A (fr) 1984-11-30
ZA831833B (en) 1983-11-30

Similar Documents

Publication Publication Date Title
ES520692A0 (es) Un procedimiento de preparacion de conjugados inmunoenzimaticos.
ES8101384A1 (es) Procedimiento de preparacion de productos citotoxicos
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
ZA875176B (en) Immunotozins,process for their preparation and pharmaceutical compositions in which they are present
FI853389A0 (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
DE3854999T2 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
FI970299A0 (fi) Oligomeeriset kantajamolekyylit, joissa on määritetysti sisällytettyjä merkitsinryhmiä ja hapteeneja
NO882518D0 (no) Fremgangsmaater ved forbedret binding til antistoff, antistoff-fragmenter, hormoner og andre bindingsmidler, og konjugater derav.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401